OBJECTIVES: To assess the association of weight loss and insulin sensitivity, glucose tolerance, and metabolic syndrome (MS) in obese adolescents following weight loss treatment, and to determine the threshold amount of weight loss required to observe improvements in these measures. STUDY DESIGN: A randomized, controlled behavioral weight loss trial was conducted with 113 obese adolescents. Changes in fasting insulin, homeostasis model assessment of insulin resistance, whole body insulin sensitivity index (WBISI), body mass index (BMI), and MS criteria were assessed at baseline and at month 4. RESULTS: There was significant improvement in all measures of insulin sensitivity at month 4. Mean fasting insulin dropped from 22.3 to 16.6 μU/mL (P < .0001). Homeostasis model assessment of insulin resistance decreased significantly from 4.9 to 3.7 (P = .001) and WBISI increased significantly from 2.87 to 3.98 (P < .0001). An 8% reduction in BMI led to a significant improvement in WBISI (P = .03) and was the optimal threshold. Fewer individuals met criteria for MS after weight loss (P = .0038), although there were no significant changes in the individual features of the syndrome. CONCLUSIONS: In this trial, weight loss at month 4 was associated with improved insulin sensitivity in obese adolescents. An approximate decrease in BMI of 8% was the threshold level at which insulin sensitivity improved. As more weight loss programs are designed for obese adolescents, it will be important to have reasonable weight loss goals that will yield improvements in metabolic and cardiovascular disease risk factors.
RCT Entities:
OBJECTIVES: To assess the association of weight loss and insulin sensitivity, glucose tolerance, and metabolic syndrome (MS) in obese adolescents following weight loss treatment, and to determine the threshold amount of weight loss required to observe improvements in these measures. STUDY DESIGN: A randomized, controlled behavioral weight loss trial was conducted with 113 obese adolescents. Changes in fasting insulin, homeostasis model assessment of insulin resistance, whole body insulin sensitivity index (WBISI), body mass index (BMI), and MS criteria were assessed at baseline and at month 4. RESULTS: There was significant improvement in all measures of insulin sensitivity at month 4. Mean fasting insulin dropped from 22.3 to 16.6 μU/mL (P < .0001). Homeostasis model assessment of insulin resistance decreased significantly from 4.9 to 3.7 (P = .001) and WBISI increased significantly from 2.87 to 3.98 (P < .0001). An 8% reduction in BMI led to a significant improvement in WBISI (P = .03) and was the optimal threshold. Fewer individuals met criteria for MS after weight loss (P = .0038), although there were no significant changes in the individual features of the syndrome. CONCLUSIONS: In this trial, weight loss at month 4 was associated with improved insulin sensitivity in obese adolescents. An approximate decrease in BMI of 8% was the threshold level at which insulin sensitivity improved. As more weight loss programs are designed for obese adolescents, it will be important to have reasonable weight loss goals that will yield improvements in metabolic and cardiovascular disease risk factors.
Authors: Phyllis W Speiser; Mary C J Rudolf; Henry Anhalt; Cecilia Camacho-Hubner; Francesco Chiarelli; Alon Eliakim; Michael Freemark; Annette Gruters; Eli Hershkovitz; Lorenzo Iughetti; Heiko Krude; Yael Latzer; Robert H Lustig; Ora Hirsch Pescovitz; Orit Pinhas-Hamiel; Alan D Rogol; Shlomit Shalitin; Charles Sultan; Daniel Stein; Pnina Vardi; George A Werther; Zvi Zadik; Nehama Zuckerman-Levin; Zeev Hochberg Journal: J Clin Endocrinol Metab Date: 2004-12-14 Impact factor: 5.958
Authors: Paul Zimmet; K George Mm Alberti; Francine Kaufman; Naoko Tajima; Martin Silink; Silva Arslanian; Gary Wong; Peter Bennett; Jonathan Shaw; Sonia Caprio Journal: Pediatr Diabetes Date: 2007-10 Impact factor: 4.866
Authors: Z Radikova; J Koska; M Huckova; L Ksinantova; R Imrich; M Vigas; T Trnovec; P Langer; E Sebokova; I Klimes Journal: Exp Clin Endocrinol Diabetes Date: 2006-05 Impact factor: 2.949
Authors: Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: Gabriel Q Shaibi; Martha L Cruz; Geoff D C Ball; Marc J Weigensberg; George J Salem; Noe C Crespo; Michael I Goran Journal: Med Sci Sports Exerc Date: 2006-07 Impact factor: 5.411
Authors: Robert I Berkowitz; Ken Fujioka; Stephen R Daniels; Alison G Hoppin; Stanford Owen; Arlette C Perry; Melinda S Sothern; Cheryl L Renz; Mark A Pirner; Julia K Walch; Olga Jasinsky; Ann C Hewkin; Vicky A Blakesley Journal: Ann Intern Med Date: 2006-07-18 Impact factor: 25.391
Authors: K M Utzschneider; R L Prigeon; J Tong; F Gerchman; D B Carr; S Zraika; J Udayasankar; B Montgomery; A Mari; S E Kahn Journal: Diabetologia Date: 2007-10-11 Impact factor: 10.122
Authors: Alwyn S Todd; Steven J Street; Jenny Ziviani; Nuala M Byrne; Andrew P Hills Journal: Int J Environ Res Public Health Date: 2015-02-17 Impact factor: 3.390